Given MYC and SMAD4 are known to be modulated by statins [57,58], the phenotypic switch caused by high and low doses of the same uPAR modulator may become an interesting research topic to elucidate whether these cancer driver genes could also serve as surrogate markers in anti-cancer therapies. This evidence concerns the gene SMAD4 and cancer.